Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738815 · ClinicalTrials.gov registry record · Early Phase 1
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
A Early Phase 1 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 43
- Enrollment target
NCT01738815 is a Early Phase 1 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 43 participants.
The verdict
NCT01738815, a Early Phase 1 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.
Interventions
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01738815
The ClinicalTrials.gov registry entry for NCT01738815 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valproic Acid is the first listed.
NCT01738815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01738815 about?
NCT01738815 is a clinical study titled "Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer". The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth.
What is the current status of trial NCT01738815?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 43 participants. The study started on 2011-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01738815?
The interventions under investigation include: Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT01738815?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.